Adrian Wan

Laboratory Manager and Operations Manager

Adrian has a background in molecular biology and biochemistry and has a passion for building teams. As the Laboratory Research and Operations Manager, he is responsible for the day-to-day activities/functions of the Aparicio research laboratory and a team of technicians, as well as overseeing the departmental responsibilities and the safety of 160+ staff members. In 2019, Adrian received his MBA from Simon Fraser University in Management of Technology. He believes technology will play a big role in all businesses in the near future. Finding a way to harness and deploy technologies in academic research, where funding is limited, will help drive efficiencies and increase productivity in academic setting and biotechnology sectors. Outside of work, Adrian’s interest includes traveling, cooking, and playing sports (mostly hockey).


Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors.

Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.

Engineered in-vitro cell line mixtures and robust evaluation of computational methods for clonal decomposition and longitudinal dynamics in cancer.

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.

CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.

Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers.

Clonal genotype and population structure inference from single-cell tumor sequencing.

Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer.

A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation.

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.

PyClone: statistical inference of clonal population structure in cancer.

Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.